Related Experiment Videos
Designer drugs – still a threat?
Emil Bartosz Rozenek1, Karolina Wilczyńska2, Monika Górska3
1Medical University of Bialystok, Students’ Scientific Circle at the Department of Psychiatry
Przeglad Epidemiologiczny
|November 27, 2019
Summary
Poland faces a growing challenge with new psychoactive substances (NPSs), often called designer drugs. This review details their evolving legal status, classification, and the significant health risks they pose, especially synthetic cannabinoids.
Area of Science:
- Forensic Chemistry
- Toxicology
- Public Health
Background:
- Poland is experiencing a rise in prohibited psychoactive substances, including new psychoactive substances (NPSs).
- The rapid synthesis of new designer drug derivatives outpaces legal controls, leading to continuous market emergence.
- Recent legal amendments in Poland (July 2018) now classify NPSs as drugs, with synthetic cannabinoids and cathinone derivatives being predominant.
Purpose of the Study:
- To consolidate current information on designer drugs in Poland.
- To define designer drugs within the context of Polish legislation.
- To categorize designer drugs by clinical effects and outline associated threats.
Main Methods:
- Literature review of reports and articles published between 2015 and 2019.
- Analysis of legal definitions and classifications of designer drugs in Poland.
- Examination of the current designer drug market landscape in Poland.
Main Results:
- Designer drugs are a significant and evolving issue in Poland, with new substances constantly appearing.
- Synthetic cannabinoids pose a particular danger due to their potential for lethal somatic toxicity.
- Rapid identification of poisonings, especially from synthetic opioids, is critical for timely intervention with antidotes.
Conclusions:
- The legal framework in Poland is adapting to the challenges posed by NPSs.
- Understanding the specific risks of different designer drugs, like synthetic cannabinoids, is crucial for public health.
- Effective monitoring and rapid response strategies are essential to mitigate the harms of the designer drug market.